Biomarkers for Diabetes

Molecular Biomarkers can be demarcated as “a characteristic that is accurately measured and gauged as an pointer of normal biological procedures, pathogenic procedures, or pharmacologic responses to a pharmaceutical intervention. Biomarkers play an vital part in leading clinical trials and treating patients. Advances in molecular diagnostics help medical professionals make knowledgeable, scientifically valid decisions. More well-organized discovery and usage of biomarkers in the growth of antidiabetes drugs will depend on accelerating our understanding of the pathogenesis of diabetes and specifically its macro-vascular complications.  Procedural improvements from other fields, especially cancer, are beginning to show the way towards better models of diabetes pathogenesis and molecular biomarker discovery.

  • Prognostic Marker
  • Diabetic Neuropathic Marker
  • MolecMarker for Both Metabolic Syndrome & Hypoglycemia response
  • Genetic Lifestyle Interaction in the development & prevention of Diabetes

Related Conference of Biomarkers for Diabetes

October 30-November 01, 2017

10th International Conference on Endocrinology

Chicago, Illinois, USA
December 04-05, 2017

25th Global Diabetes Summit and Medicare Expo

Dubai, UAE
March 8-9, 2018

17th Global Diabetes Conference & Nursing Care

| Paris, France
May 23-24, 2018

11th Diabetologists Conference

New York, USA
June 20-21, 2018

27th European Diabetes Congress

| Rome, Italy
July 16-17, 2018 Sydney, Australia

20th Asia Pacific Diabetes Conference

August 20-21, 2018

28th World Congress on Diabetes, Obesity & Heart

Tokyo, Japan
September 03-04, 2018

2nd International Conference on Thyroid and Pregnancy

Auckland, New Zealand
September 3-4, 2018

11th World Congress on Endocrinology and Metabolic Disorders

Auckland, New Zealand
November 26-27, 2018

13th European Diabetes and Endocrinology Congress

Dublin, Ireland

Biomarkers for Diabetes Conference Speakers